View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

EQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Establishes an At-the-Market (ATM) Program on Nasdaq 19.11.2024 / 22:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in p...

 PRESS RELEASE

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allowing the Company to issue and sell, i...

 PRESS RELEASE

EQS-News: Abivax presents third quarter 2024 key financial information

EQS-News: ABIVAX / Key word(s): Quarter Results Abivax presents third quarter 2024 key financial information 14.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax presents third quarter 2024 key financial information  PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory respon...

 PRESS RELEASE

Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the...

Thijs Berkelder ... (+2)
  • Thijs Berkelder
  • Usama Tariq

ODDO BHF Small & MIDCAP MORNING NEWS - Date1

We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...

Thijs Berkelder ... (+2)
  • Thijs Berkelder
  • Usama Tariq

ODDO BHF Small & MIDCAP MORNING NEWS - 11/14/2024

We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Interparfums : Feedback from the CMD: slight downward adjustment to es...

>Key takeaways: cautious guidance, less ambitious on Moncler and work to be done on enhancing the portfolio - 1/ Cautious guidance for 2025 (but the consensus too high), due to embedded effects. A good line-up for 2025: several launch initiatives are planned: Montblanc Explorer (new line), Jimmy Choo Man, Coach (2 new editions: Woman and Man), Solferino (new proprietary brand - niche perfumes / 10 lines listed in Paris for the story telling), Lacoste (extension of L12...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Interparfums : Feedback CMD : estimations légèrement abaissées

>Principaux éléments : guidance prudente, moins ambitieux sur Moncler et un travail à réaliser pour enrichir le portefeuille - 1/ Guidance 2025 prudente (mais CSS trop haut), compte tenu des effets embarqués. Bon line-up en 2025: plusieurs initiatives de lancements sont prévues : Montblanc Explorer (nouvelle ligne), Jimmy Choo Man, Coach (2 nouvelles déclinaisons : Woman et Man), Solferino (nouvelle marque propriétaire - parfums de niche / 10 lignes en référence à Par...

Loic Morvan
  • Loic Morvan

Interparfums: cautious prospects for 2025

Interparfums management released cautious sales prospects for 2025 yesterday with limited growth despite the roll-out of Lacoste Original. Although we are slightly more aggressive than management, we have notched down our FY25 sales estimate from EUR960m to EUR950m. Buy reiterated with EUR54 vs EUR

 PRESS RELEASE

EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appo...

EQS-News: ABIVAX / Key word(s): Personnel Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax 13.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural ...

 PRESS RELEASE

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as B...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Bo...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Interparfums : CMD and guidance: 2024 landing confirmed, cautious 2025...

>The management guides to 2025 growth of “just” 4%e - Ahead of its CMD today, Interparfums announced:1/ The fine tuning of its 2024 guidance: i/ 2024 sales are maintained in a range of between € 880-890m), ii/ the 2024 underlying operating margin is now projected to exceed 19%e, or >€ 170m est. (vs close to 19%, i.e. € 167-170m est. previously),2/ 2025 sales between € 910m and € 930m est. (i.e. +4% at the midpoint) , vs css >€ 950m est.;3/ A 2025 operat...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Interparfums : CMD et guidances : atterrissage 2024 conforté, perspect...

>Le management guide sur une croissance 2025 de « seulement » 4%e - En amont de son CMD, qui se tiendra aujourd’hui, Interparfums communique sur :1/ Le fine tuning de sa guidance 2024 : i/ le CA 24e est maintenu à une fourchette comprise entre 880-890 M€ précédemment), ii/ la MOp. courante 2024 devrait désormais dépasser les 19%e, soit >170 M€e (vs proche de 19% ie. 167-170 M€e jusqu’ici).2/ Un CA 2025 compris entre 910 et 930 M€e (ie. +4% en milieu de fourc...

Mahaut Arnaud ... (+3)
  • Mahaut Arnaud
  • Paul de Froment
  • Thomas Mordelle

Ebusco: strategic partnership with Gotion, launch of EUR36m rights iss...

Ebusco has announced a strategic partnership with Gotion, a company specialised in power battery technologies, building on their collaboration started in 2018. The partnership will focus on enhancing Ebusco's lightweight buses with Gotion's advanced battery tech, expanding into the Asian market, an

 PRESS RELEASE

GTT: Monthly disclosure of the total number of voting rights and share...

GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, November 7, 2024 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2October 31, 202437,117,77237,117,77237,049,337 Investor Relations Contact          / 87                         1 Calculat...

 PRESS RELEASE

GTT : Information mensuelle relative au nombre total de droits de vote...

GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 7 novembre 2024 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets231 octobre 202437.117.77237.117.77237.049.337 Contact Relations Investisseurs : / 87      ...

Jean-François Granjon
  • Jean-François Granjon

GTT : Confirmation du haut de fourchette des guidances

>Publication du CA T3/9 mois légèrement supérieur à nos attentes - GTT publie un CA 9 mois de 464.7 M€ (458.8 M€ estimés, 454.9 M€ pour le consensus) vs 300 M€ en hausse de 54.9%. Au titre du seul CA T3, la hausse ressort à +42%. Il s’agit d’une bonne performance au regard d’un effet de référence soutenu (+53.8%). Cette dynamique s’inscrit dans la continuité d’un carnet de commandes extrêmement soutenu. L’activité Nouvelle constructions (92% du total) affiche un CA d...

Juan Ros-Padilla ... (+2)
  • Juan Ros-Padilla
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 11/05/2024

European equity markets weakened in October following multiple disappointments across the earnings season. The impending US election, the outcome of which is highly uncertain according to the polls, may also have prompted some traders to adopt a cautious stance. Sovereign long rates rose sharply, particularly in the US, on the back of macro indicators likely to provide arguments to the most hawkish of central bankers. All eyes are now on the November 5 elections and their repercussion...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch